Therapeutic Exploitation of Endogenous Anti-Inflammatory Mechanisms:Old and New Leads

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)


Volume 15, 3 Issues, 2016


Download PDF Flyer




Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Claudiu T. Supuran
Neurofarba Department
University of Florence
Florence
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Therapeutic Exploitation of Endogenous Anti-Inflammatory Mechanisms:Old and New Leads



Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 5(4): 289-305.

Author(s): D. Renshaw, P. Urquhart and M Perretti.

Affiliation: William Harvey Research Institute, Bart's and the London, Queen Mary School of Medicine and Dentistry,Charterhouse Square, London EC1M 6BQ, United Kingdom.

Abstract

Understanding the way our body switches off host defence responses has yielded some of the most innovative recent discoveries in inflammation research. In reality the concept is not new, and was already implicit in early publications of the 1970s which showed that during inflammation, glucocorticoids are increased in the circulation and that these protect the host from over-shooting and ensuing self-inflicted injury. Stemming from the first example of drugs developed on an endogenous anti-inflammatory pathway, that of the glucocorticoid, we have here touched upon other counterregulatory breakpoints, such as those centred on melanocortins; the annexin 1 system; the polyunsaturated fatty acid derivatives lipoxins and resolvins; galectin-1 and selected others, including novel chemical entities engineered to release anti-inflammatory gases and factors originally discovered in the developmental field. We propose that understanding the molecular mechanisms switched on by a given anti-inflammatory mediator and the events it modulates in target cells will be of great help in developing innovative ways to control inflammatory pathologies. This seems quite articulated and with a degree of complexity in the group of developmental axonal guidance factors. We propose that drugs discovered along this philosophy will have a better compliance and would be theoretically devoid of side effects since they will be acting by mimicking the way our own body assures the inflammatory response is restricted both spatially and temporally.

Keywords:

Glucocorticoids, anti-inflammation, lipocortin 1, neutrophil, melanocortins, galectin-1, lipoxins, resolvins.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 5
Issue Number: 4
First Page: 289
Last Page: 305
Page Count: 17
DOI: 10.2174/187152306778772838
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science